【摘要】 目的设计合成缩氨基胍类化合物并研究其NHE1抑制活性。方法以4-取代苯乙酮(1)为原料,经溴代得α-溴代物(2),再与2-巯基-5-取代苯并咪(噻)唑(3)反应得到2-(5-取代苯并咪(噻)唑-2-硫基)-1-(4-取代苯基)乙酮(4),最后与氨基胍缩合得到目标化合物;以血小板肿胀模型进行初步的体外NHE1抑制活性筛选。结果与结论合成了12个新化合物,其结构经IR、1H-NMR及MS确证。初步的药理试验表明,12个目标化合物均有一定的NHE1抑制活性,其中化合物5b和5h的活性明显优于阳性对照药卡立泊来德。更多还原

【Abstract】 Aim In order to get some novel compounds with potent NHE1 inhibitory activity for the prevention and treatment of myocardial injury during ischemia and reperfusion,12 target compounds of [2-(5-substituted benzimidazol(or benzothiazol)-2-ylthio)-1-(4-substituted phenylethylidene)] aminoguanidines(5a-5l)were synthesized.Methods Firstly,treatment of 4-substituted phenylethanone(1)with bromine gave alpha-bromophenylethanone intermediates(2).Secondly,substitution of the bromo group of 2 by 2-mercapto-5-substitutedbenzimidazole(or benzothiazole)(3)afforded 2-(5-substitutedbenzimidazole(or benzothiazole)-2-ylthio)-1-(4-substitutedphenyl)ethanone(4).Finally,condensation of 3 with aminoguanidine furnished the target compounds 5a-5l.Results and conclusion The structures of the compounds were confirmed by IR,MS,and 1H-NMR.The results of preliminary pharmacological test showed that all of compounds possess diverse NHE1 inhibitory activity,among which compounds 5b and 5h were more potent than cariporide in NHE1 inhibiton.更多还原